Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862666 | 0.92 | KMT2A (0.49) | KMT2ANPSR1CACNA1BCYP2D6MAPT | |
| SCHEMBL5862644 | 0.91 | KMT2A (0.58) | KMT2ANPSR1CACNA1BCYP2D6MAPT | |
| SCHEMBL5861027 | 0.89 | KMT2A (0.47) | KMT2ANPSR1CYP2D6MAPTKLKB1 | |
| SCHEMBL5860024 | 0.89 | KMT2A (0.44) | KMT2ANPSR1CACNA1BCYP2D6MAPT | |
| SCHEMBL5860000 | 0.88 | KMT2A (0.43) | KMT2ANPSR1CYP2D6MAPTKLKB1 | |
| SCHEMBL5861047 | 0.83 | KMT2A (0.59) | KMT2ANPSR1CYP2D6MAPTKLKB1 | |
| SCHEMBL6150797 | 0.83 | NPSR1 (0.59) | KMT2ANPSR1CYP2D6MAPTKLKB1 | |
| SCHEMBL5859782 | 0.82 | KMT2A (0.47) | KMT2ANPSR1CYP2D6MAPTKLKB1 | |
| SCHEMBL5859898 | 0.82 | KMT2A (0.47) | KMT2ANPSR1CYP2D6MAPTKLKB1 | |
| SCHEMBL5861059 | 0.81 | KMT2A (0.46) | KMT2ANPSR1CYP2D6MAPTKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144364-B1 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2005-07-13 | — | — | EP | claimed |
| US-6465513-B1 | SUCH AS N-(ADAMANT-1-YLCARBONYL)-L-4-(N,N-DIMETHYLCARBAMYL-OXY)PHENYLALANINE; INFLAMMATORY DISEASES SUCH AS ASTHMA, AIDS DEMENTIA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | claimed |
| US-7115768-B2 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060074110-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1144364-B1 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20030134874-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | GRANT FRANCINE S (US) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134874-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | KMT2A 1620/4885NPSR1 1381/4885CACNA1B 842/4885 |
| US-20060074110-A1 | Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | KMT2A 1620/4885NPSR1 1381/4885CACNA1B 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.